Attached files
| file | filename |
|---|---|
| EX-4.4 - ADMA BIOLOGICS, INC. | e614766_ex4-4.htm |
| EX-31.2 - ADMA BIOLOGICS, INC. | e614766_ex31-2.htm |
| EX-32.2 - ADMA BIOLOGICS, INC. | e614766_ex32-2.htm |
| EX-10.8 - ADMA BIOLOGICS, INC. | e614766_ex10-8.htm |
| EX-32.1 - ADMA BIOLOGICS, INC. | e614766_ex32-1.htm |
| EX-10.2 - ADMA BIOLOGICS, INC. | e614766_ex10-2.htm |
| EX-31.1 - ADMA BIOLOGICS, INC. | e614766_ex31-1.htm |
| EX-10.11 - ADMA BIOLOGICS, INC. | e614766_ex10-11.htm |
| EX-10.3.1 - ADMA BIOLOGICS, INC. | e614766_ex10-31.htm |
| 10-K - ADMA BIOLOGICS, INC. | e614766_10k-adma.htm |
| EX-10.10 - ADMA BIOLOGICS, INC. | e614766_ex10-10.htm |
Exhibit 23.1
Consent of Independent Registered
Public Accounting Firm
We consent to the incorporation by reference in the registration statements on Form S-8 (File Nos. 333-193635 and 333-204590) and Form S-3 (File No. 333-200638) filed by ADMA Biologics, Inc. of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 23, 2016, on our audits of the consolidated financial statements of ADMA Biologics, Inc. and Subsidiaries as of December 31, 2015 and 2014 and for the years then ended, included in this Annual Report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2015.
/s/ CohnReznick LLP
Roseland, New Jersey
March 23, 2016